Koren W, Koldanov R, Pronin V S, Postnov I Y, Peleg E, Rosenthal T, Berezin M, Postnov Y V
Hypertension Unit, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Diabetologia. 1997 Mar;40(3):302-6. doi: 10.1007/s001250050678.
Intensive treatment of non-insulin-dependent diabetes mellitus (NIDDM) decreases the rate of microvascular complications, but is associated with increased incidence of cardiovascular morbidity. Enhanced permeability of plasma membranes for sodium (e.g. sodium-hydrogen exchange, NHE) may predict the subset of diabetic patients for whom intensive modalities of treatment are indicated despite their potential risk. However, the accuracy of NHE as a marker of microangiopathy has not been assessed. In this study NHE as initial velocity of amiloride-inhibited H+ efflux from erythrocytes (pHi 6.35-6.45) into an Na(+)-containing medium (pHo 7.95-8.05), was estimated during 8 years of follow-up in 138 non-microalbuminuric diabetic patients (74 women, 64 men, age 52 +/- 4 years) treated with antihyperglycaemic drugs for 14 +/- 2 years. Appearance of microalbuminuria, overt proteinuria, azotaemia and retinopathy was assessed annually. Enhanced erythrocyte NHE predicted diabetic nephropathy alone and in association with a family history of hypertension and/or nephropathy with a sensitivity of 86 and 93%, respectively. No association was found between NHE and retinopathy in NIDDM. It is concluded that assessment of erythrocyte NHE can identify a subset of patients likely to develop renal damage, for whom an aggressive treatment approach might be considered.
非胰岛素依赖型糖尿病(NIDDM)的强化治疗可降低微血管并发症的发生率,但与心血管疾病发病率的增加有关。细胞膜对钠的通透性增强(例如钠-氢交换,NHE)可能预示着尽管存在潜在风险,但仍需强化治疗的糖尿病患者亚组。然而,NHE作为微血管病变标志物的准确性尚未得到评估。在本研究中,在138例非微量白蛋白尿糖尿病患者(74例女性,64例男性,年龄52±4岁)接受降糖药物治疗14±2年的8年随访期间,估计了NHE作为氨氯地平抑制的H⁺从红细胞(细胞内pH值6.35 - 6.45)流入含钠介质(细胞外pH值7.95 - 8.05)的初始速度。每年评估微量白蛋白尿、显性蛋白尿、氮质血症和视网膜病变的出现情况。红细胞NHE增强单独预测糖尿病肾病以及与高血压和/或肾病家族史相关的糖尿病肾病,敏感性分别为86%和93%。在NIDDM中未发现NHE与视网膜病变之间存在关联。结论是,评估红细胞NHE可以识别出可能发生肾损害的患者亚组,对于这些患者可能需要考虑积极的治疗方法。